Skip to main content

Clincierge Releases Study on Patient Experience in Clinical Trials

PHILADELPHIA and SAN DIEGO , June 14, 2022. Clincierge today released "Voice of the Patient," a research report examining the patient experience in clinical trials of rare diseases, at the 2022 BIO International Convention in San Diego, California.

"Patient recruitment and retention are two of the most pressing challenges facing clinical research, especially in studies targeting rare diseases where the patient pool is limited," said Scott Gray, CEO, Clincierge. "The future of all clinical trials lies in our collective ability and willingness to put patient experience at the center of trial design."

Findings in "Voice of the Patient" include:

Data in the report is the result of an independent study commissioned by Clincierge and conducted by Insight and Measurement over the course of the previous year. The study began with a qualitative phase including writing prompts and online journaling, while a second quantitative phase compiled data via an institutional review board (IRB) approved survey.

"What struck me was the dichotomy between wanting to take part in clinical trials but feeling overwhelmed by the logistics. One patient wrote, 'There were just so many things to plan and deal with and manage,' while another said they felt, 'a great deal of satisfaction in participating,'" said David Harris, president, Insight and Measurement.

About Clincierge
Clincierge is the leading provider of patient support services for clinical trials. Clincierge's global team of patient care coordinators manages the logistics of trial participation for patients and their caregivers, including travel and reimbursement. Since 2015, Clincierge has coordinated patient logistics in more than 300 clinical trials around the world. For more information, visit www.clincierge.com.

SOURCE Clincierge

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.